Canakinumab (Synonyms: Ilaris; ACZ 885) |
| Catalog No.GC66328 |
Le canakinumab (ACZ885) est un anti-IL-1β humain recombinant ; anticorps monoclonal. Le canakinumab montre des valeurs IC50 de 43,6 et 40,8 pM pour l'IL-1β humaine et marmouset, respectivement. Le mode d'action du canakinumab est basé sur la neutralisation de l'IL-1β ; signalisation, entraÎnant la suppression de l'inflammation liée aux troubles d'origine auto-immune.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 914613-48-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 43.6 pM (human IL-1β), 40.8 pM (marmoset IL-1β)[2]
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin[1][2].
Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β[2].Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b[2].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *